Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

Zhu,Yanyan; Guo,Meiyan; Zhang,Lingyun; Xu,Tao; Wang,Li; Xu,Guoxiong

doi:10.3892/or.2015.4391

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

Authors:
- Yanyan Zhu
- Meiyan Guo
- Lingyun Zhang
- Tao Xu
- Li Wang
- Guoxiong Xu
View Affiliations

Affiliations: Department of General Surgery, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056002, P.R. China, Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Health Check‑Up Center, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China, Department of Pathology, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China
Published online on: November 3, 2015 https://doi.org/10.3892/or.2015.4391
Pages: 454-462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The early detection of breast cancer, the most common malignant tumor disease in women worldwide, relies on mammography and self breast examination. Here we evaluated the concentration of nicotinamide phosphoribosyltransferase (NAMPT), vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor‑2 (HER2) in serum and their expression in breast tissues associated with the clinicopathological features of patients with benign and malignant breast tumors. The immunohistochemical analysis showed that NAMPT, VEGF and HER2 proteins were overexpressed in breast tumors. The highest expression was observed in malignant tumors, low in benign tumors and negative in the adjacent normal tissue, indicating that the triplets may be progression markers and correlated with each other. The detection rate of NAMPT, VEGF and HER2 alone in tissue was 54.17, 64.58 and 60.42%, respectively, and was increased to about 79% in double combination and to 90% in triple combination. The basal levels of serum NAMPT, VEGF and HER2 in healthy controls were 94.90±4.24 pg/ml, 87.02±2.41 pg/ml and 1.12±0.04 ng/ml, respectively, measured by ELISA and found to be increased by 6.64‑, 1.76‑ and 2.52‑fold, respectively, in patients with malignant breast tumor. These elevated serum levels of NAMPT, VEGF and HER2 in patients were decreased after tumor removal, suggesting that these molecules are the indicators of treatment efficacy. The combined measurement of these triplets together may improve the sensitivity of breast cancer diagnosis and may potentially be used as a testing panel for the detection of malignant tumors, the assessment of treatment effectiveness and the monitoring of the disease progression in patients with breast cancer. Thus, we propose that the biomarker triplet NAMPT/VEGF/HER2 can be used as a de novo detection panel for the diagnosis and prognosis of human breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, et al: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science. 307:426–430. 2005. View Article : Google Scholar
3	Samal B, Sun Y, Stearns G, Xie C, Suggs S and McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 14:1431–1437. 1994. View Article : Google Scholar : PubMed/NCBI
4	Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, Li HJ and Zhao W: Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol Rep. 26:1251–1257. 2011.PubMed/NCBI
5	Wang B, Hasan MK, Alvarado E, Yuan H, Wu H and Chen WY: NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 30:907–921. 2011. View Article : Google Scholar
6	Hufton SE, Moerkerk PT, Brandwijk R, de Bruïne AP, Arends JW and Hoogenboom HR: A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 463:77–82. 1999. View Article : Google Scholar : PubMed/NCBI
7	Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruïne AP, Arends JW, Hoogenboom HR and Hufton SE: Target validation for genomics using peptide-specific phage antibodies: A study of five gene products overexpressed in colorectal cancer. Int J Cancer. 101:118–127. 2002. View Article : Google Scholar : PubMed/NCBI
8	Shackelford RE, Bui MM, Coppola D and Hakam A: Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol. 3:522–527. 2010.PubMed/NCBI
9	Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, et al: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res. 11:7434–7443. 2005. View Article : Google Scholar : PubMed/NCBI
10	Shackelford R, Hirsh S, Henry K, Abdel-Mageed A, Kandil E and Coppola D: Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. Anticancer Res. 33:3047–3052. 2013.PubMed/NCBI
11	Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G, Ma X, Sun D, Rohan T and Xue F: Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol Oncol. 129:505–512. 2013. View Article : Google Scholar : PubMed/NCBI
12	Maldi E, Travelli C, Caldarelli A, Agazzone N, Cintura S, Galli U, Scatolini M, Ostano P, Miglino B, Chiorino G, et al: Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions. Pigment Cell Melanoma Res. 26:144–146. 2013. View Article : Google Scholar
13	Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, et al: PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther. 7:663–668. 2008. View Article : Google Scholar : PubMed/NCBI
14	Dalamaga M, Archondakis S, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E and Lekka A: Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas. 71:301–308. 2012. View Article : Google Scholar : PubMed/NCBI
15	Thielemann A, Baszczuk A, Kopczyński Z, Kopczyński P and Grodecka-Gazdecka S: Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer. Ann Agric Environ Med. 20:293–297. 2013.PubMed/NCBI
16	Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S and Bundred NJ: Serum vascular endothelial growth factor in breast cancer. Anticancer Res. 27(5B): 3481–3487. 2007.PubMed/NCBI
17	Baskić D, Ristić P, Pavlović S and Arsenijević N: Serum HER2 and CA 15-3 in breast cancer patients. J BUON. 9:289–294. 2004.
18	Rocca A, Cancello G, Bagnardi V, Sandri MT, Torrisi R, Zorzino L, Viale G, Pietri E, Veronesi P, Dellapasqua S, et al: Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. Anticancer Res. 29:5111–5119. 2009.
19	Wang X, Gui L, Zhang Y, Zhang J, Shi J and Xu G: Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway. Int J Oncol. 44:1099–1106. 2014.PubMed/NCBI
20	Dalamaga M, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G and Lekka A: Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters. Menopause. 18:1198–1204. 2011. View Article : Google Scholar : PubMed/NCBI
21	Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K, Tavelin B, Grankvist K and Henriksson R: Over-expression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer. 40:33–42. 2004. View Article : Google Scholar
22	Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M and Mokbel K: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin. 18:237–241. 2002. View Article : Google Scholar : PubMed/NCBI
23	Li XY, Tang SH, Zhou XC, Ye YH, Xu XQ and Li RZ: Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women. Peptides. 51:86–90. 2014. View Article : Google Scholar
24	Lam L, Czerniecki BJ, Fitzpatrick E, Xu S, Schuchter L, Xu X and Zhang H: Interference-free HER2 ECD as a serum biomarker in breast cancer. J Mol Biomark Diagn. 4:1512014.PubMed/NCBI
25	Santidrian AF, LeBoeuf SE, Wold ED, Ritland M, Forsyth JS and Felding BH: Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer. DNA Repair (Amst). 23:79–87. 2014. View Article : Google Scholar
26	Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, Mastracci L, Boero S, Montecucco F, Sociali G, et al: Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. J Biol Chem. 289:34189–34204. 2014. View Article : Google Scholar : PubMed/NCBI
27	Lee YC, Yang YH, Su JH, Chang HL, Hou MF and Yuan SS: High visfatin expression in breast cancer tissue is associated with poor survival. Cancer Epidemiol Biomarkers Prev. 20:1892–1901. 2011. View Article : Google Scholar : PubMed/NCBI
28	Dalamaga M: Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Med Hypotheses. 79:617–621. 2012. View Article : Google Scholar : PubMed/NCBI
29	Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, Diadema MR, Aurilio G, Santabarbara G, Ruggiero R, et al: Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 over-expression in endocrine positive primary breast cancer. Cancer Invest. 26:250–255. 2008. View Article : Google Scholar : PubMed/NCBI
30	Lissoni P, Fugamalli E, Malugani F, Ardizzoia A, Secondino S, Tancini G and Gardani GS: Chemotherapy and angiogenesis in advanced cancer: Vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer. Int J Biol Markers. 15:308–311. 2000.
31	Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells. 16:413–428. 1998. View Article : Google Scholar : PubMed/NCBI
32	Park IH, Lee KS, Kang HS, Kim SW, Lee S, Jung SY, Kwon Y, Shin KH, Ko K, Nam BH, et al: A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer. Invest New Drugs. 30:1972–1977. 2012. View Article : Google Scholar